3963 MAPLE AVENUE, DALLAS, TX
Market cap: $52.7M (2/10/2026)
Price: $7.77
Termination of License Agreement with ImmuneOnco - Axion Bio, Inc.
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Other Events
Shareholder votes
Phase 2 Trial of IMM2510/AXN-2510 in NSCLC on Track for Q3 2025 Enrollment
Investor Presentation
Reports First Quarter 2025 Financial Results and Provides Corporate Update
Q2
Q1
FY 2024
Q3
FY 2023
Q3 amended
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Definitive Revised Proxy Statement
SEC Staff Correspondence
Correspondence